Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced the appointment of Mark Daniels to the newly-created position of chief ethics and compliance officer.
Mr. Daniels will maintain his current position as Twist Bioscience’s general counsel, and in his expanded role, will oversee the company’s ethics and compliance programs. He will continue to be integrally involved in providing guidance on wide-ranging aspects of the company’s synthetic biology business.
“Through our expertise in DNA synthesis, Twist Bioscience continues to drive the bioeconomy, fueling far-reaching innovations that will impact health and sustainability worldwide,” said Emily M. Leproust, PhD., CEO of Twist Bioscience. “Our expanding role in the bioeconomy comes with incredible responsibility to continuously evaluate the ethical impact of our business and our actions. Importantly, we view ethics and compliance as integral to our operations, with a continued focus on demonstrated leadership in biosecurity and biosafety. Ethics and Compliance will only become more important as we move forward with our pharmaceutical vertical. With that in mind, we are formalizing the role and identified Mark as the perfect person to fill that position.”